Published in Am J Gastroenterol on December 01, 2008
Comment on a retraction. Am J Gastroenterol (2009) 1.38
Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. Intest Res (2015) 0.89
Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol (2014) 0.84
Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol (2014) 0.79
Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients. World J Gastroenterol (2014) 0.78
6-Mercaptopurine transport in human lymphocytes: correlation with drug-induced cytotoxicity. J Dig Dis (2012) 0.77
The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol (2016) 0.76
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol (2015) 0.75
Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study. Medicine (Baltimore) (2016) 0.75
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology (2013) 2.78
Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol (2012) 2.73
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A (2011) 2.12
Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol (2013) 2.05
Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med (2014) 2.04
Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut (2012) 1.97
Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut (2010) 1.93
Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut (2010) 1.92
Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol (2013) 1.86
Preventing postoperative recurrence in Crohn's disease: what does the future hold? Drugs (2013) 1.55
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol (2010) 1.54
Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol (2008) 1.52
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut (2011) 1.52
Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis (2013) 1.49
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol (2011) 1.49
Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease. J Gastrointest Surg (2013) 1.42
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease. Inflamm Bowel Dis (2015) 1.38
Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol (2011) 1.26
Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis (2010) 1.26
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol (2010) 1.22
Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut (2013) 1.22
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest (2014) 1.20
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol (2010) 1.15
Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis (2012) 1.12
Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med (2013) 1.08
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis (2011) 1.07
Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis (2011) 1.07
Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.07
Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis (2013) 1.06
Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases. World J Gastroenterol (2011) 1.05
Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis (2011) 1.05
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis (2013) 1.04
Lewis and Sumner syndrome following infliximab treatment in Crohn's disease: a report of 2 cases. Inflamm Bowel Dis (2010) 1.02
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets (2010) 1.01
Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. Dig Liver Dis (2012) 0.99
Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol (2013) 0.98
XIAP as a radioresistance factor and prognostic marker for radiotherapy in human rectal adenocarcinoma. Am J Pathol (2012) 0.97
Surgery for adult Crohn's disease: what is the actual risk? Gut (2011) 0.97
Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis (2014) 0.96
Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep (2013) 0.94
Digestive smooth muscle mitochondrial myopathy in patients with mitochondrial-neuro-gastro-intestinal encephalomyopathy (MNGIE). Gastroenterol Clin Biol (2005) 0.94
Methyl donor deficiency impairs fatty acid oxidation through PGC-1α hypomethylation and decreased ER-α, ERR-α, and HNF-4α in the rat liver. J Hepatol (2012) 0.93
Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion. J Crohns Colitis (2013) 0.93
Clinical risk factors for complicated disease: how reliable are they? Dig Dis (2013) 0.93
Human herpesvirus 8-associated colorectal Kaposi's sarcoma occurring in a drug-induced immunocompromised patient with refractory ulcerative colitis: report of a new case and review of the literature. Inflamm Bowel Dis (2013) 0.90
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. Gastroenterology (2012) 0.90
Phenotype of inflammatory bowel disease at diagnosis in the Netherlands: a population-based inception cohort study (the Delta Cohort). Inflamm Bowel Dis (2013) 0.90
Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. Curr Drug Targets (2013) 0.89
Oral probiotic control skin inflammation by acting on both effector and regulatory T cells. PLoS One (2009) 0.89
Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. Am J Gastroenterol (2013) 0.89
Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis (2012) 0.88
Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2015) 0.88
Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. Clin Gastroenterol Hepatol (2013) 0.87
Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis (2011) 0.86
Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. Curr Drug Targets (2011) 0.86
Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. J Crohns Colitis (2011) 0.86
How NOD2 mutations predispose to Crohn's disease? Microbes Infect (2007) 0.86
Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm Bowel Dis (2009) 0.86
Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.85
Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis (2010) 0.85
Gossypiboma successfully removed by upper-GI endoscopy. Gastrointest Endosc (2007) 0.85
Nonfistulizing perianal Crohn's disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis (2010) 0.85
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis (2015) 0.84
Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. AJR Am J Roentgenol (2011) 0.84
Antimycobacterial therapy in Crohn's disease: game over? Gastroenterology (2007) 0.84
Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. Inflamm Bowel Dis (2008) 0.84
Transcutaneous posterior tibial nerve stimulation for fecal incontinence in inflammatory bowel disease patients: a therapeutic option? Inflamm Bowel Dis (2009) 0.84
[Pancreatic pseudocysts of the right hepatic lobe during acute biliary pancreatitis]. Gastroenterol Clin Biol (2005) 0.84
Mucosal healing with anti-TNF antibodies. Digestion (2012) 0.83
Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis (2013) 0.83
Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion (2012) 0.83
Deep remission: a new concept? Dig Dis (2013) 0.83
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease. Dig Dis Sci (2013) 0.83
Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis (2014) 0.82
Identification of Mycobacterium cosmeticum sp. as a novel colitogenic infectious agent in a nonimmunocompromised patient. Inflamm Bowel Dis (2011) 0.82
Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis (2011) 0.82
Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis (2011) 0.82
Adalimumab in ulcerative colitis: hypes and hopes. Expert Opin Biol Ther (2011) 0.82
Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci (2007) 0.81
Blockade of LTB(4) /BLT(1) pathway improves CD8(+) T-cell-mediated colitis. Inflamm Bowel Dis (2010) 0.81
Methyl deficient diet aggravates experimental colitis in rats. J Cell Mol Med (2011) 0.81
Treatment of fibrostenotic and fistulizing Crohn's disease. Digestion (2012) 0.80
Helicobacter pylori serologic status has no influence on the association between fucosyltransferase 2 polymorphism (FUT2 461 G->A) and vitamin B-12 in Europe and West Africa. Am J Clin Nutr (2012) 0.80
5-Aminosalicylic acid and chemoprevention: does it work? Dig Dis (2013) 0.80
[Intestinal permeability and cirrhosis]. Gastroenterol Clin Biol (2006) 0.80
Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis (2010) 0.79
[Probable hepatoxicity from epigallocatecol gallate used for phytotherapy]. Gastroenterol Clin Biol (2004) 0.79
Prevalence of cytomegalovirus infection in steroid-refractory Crohn's disease. Inflamm Bowel Dis (2012) 0.79
A pathologic complete response in the surgical specimen after systemic chemotherapy for a gallbladder carcinoma. Gastrointest Cancer Res (2012) 0.79
Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China. BMC Med Genet (2008) 0.78
Colon cancer after infliximab therapy for Crohn's disease in a young patient transplanted for primary sclerosing cholangitis. Am J Gastroenterol (2006) 0.78
Laparoscopic total colectomy: Does the indication influence the outcome? World J Gastrointest Surg (2011) 0.78